These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35666070)

  • 21. Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    Satyam VR; Li PH; Reich J; Qazi T; Noronha A; Wasan SK; Farraye FA
    Dig Dis Sci; 2020 Oct; 65(10):2986-2991. PubMed ID: 31897892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis.
    Patterson BJ; Chen CC; McGuiness CB; Ma S; Glasser LI; Sun K; Buck PO
    J Am Pharm Assoc (2003); 2022; 62(2):526-536.e10. PubMed ID: 34893442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
    Sun Y; Jackson K; Dalmon CA; Shapiro BL; Nie S; Wong C; Arnold BF; Porco TC; Acharya NR
    Vaccine; 2021 Jun; 39(29):3974-3982. PubMed ID: 34116874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
    Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
    J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021.
    LaMori J; Feng X; Pericone CD; Mesa-Frias M; Sogbetun O; Kulczycki A
    Vaccine; 2022 Apr; 40(15):2266-2273. PubMed ID: 35292160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
    Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
    Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis.
    Xia Y; Zhang X; Zhang L; Fu C
    Front Immunol; 2022; 13():978203. PubMed ID: 36248796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients.
    Lenfant T; Jin Y; Kirchner E; Hajj-Ali RA; Calabrese LH; Calabrese C
    Rheumatology (Oxford); 2021 Nov; 60(11):5149-5157. PubMed ID: 33560302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insurance reimbursements for recombinant zoster vaccine in the private sector.
    Leidner AJ; Tang Z; Guo A; Anderson TC; Tsai Y
    Vaccine; 2021 Aug; 39(36):5091-5094. PubMed ID: 34348844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease.
    Kochhar GS; Desai A; Caldera DO F; El Hachem S; Aoun E; Sandhu D; Mohan BP; Dulai PS; Farraye FA
    Vaccine; 2021 Jul; 39(30):4199-4202. PubMed ID: 34140170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
    Zerbo O; Bartlett J; Fireman B; Lewis N; Goddard K; Dooling K; Duffy J; Glanz J; Naleway A; Donahue JG; Klein NP
    Ann Intern Med; 2024 Feb; 177(2):189-195. PubMed ID: 38190712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients.
    Racine É; Gilca V; Amini R; Tunis M; Ismail S; Sauvageau C
    Vaccine; 2020 Sep; 38(40):6205-6214. PubMed ID: 32788132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients.
    George S; Regan J; Awan A; O'Connor M; Foster A; Raymond K; Gorfinkel I; McNeil SA
    Hum Vaccin Immunother; 2024 Dec; 20(1):2317595. PubMed ID: 38502342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019.
    Patterson BJ; Chen CC; McGuiness CB; Glasser LI; Sun K; Buck PO
    Hum Vaccin Immunother; 2021 Aug; 17(8):2482-2487. PubMed ID: 33849373
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel Disease.
    Khan N; Wang L; Trivedi C; Pernes T; Patel M; Xie D; Yang YX
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1570-1578.e1. PubMed ID: 34274513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
    Lasagna A; Mele D; Bergami F; Alaimo D; Dauccia C; Alessio N; Comolli G; Pasi F; Muzzi A; Novelli V; Baldanti F; Pedrazzoli P; Cassaniti I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288282. PubMed ID: 38037900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).
    Curran D; Matthews S; Rowley SD; Young JH; Bastidas A; Anagnostopoulos A; Barista I; Chandrasekar PH; Dickinson M; El Idrissi M; Heras I; Milliken ST; Monserrat Coll J; Navarro Matilla MB; Oostvogels L; Piątkowska-Jakubas B; Quiel D; Sabry W; Schwartz S; Selleslag DLD; Sullivan KM; Theunissen K; Yegin ZA; Yeh SP; Zaja F; Szer J;
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2474-2481. PubMed ID: 31394276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.
    Florea A; Sy L; Qian L; Ackerson B; Luo Y; Wu J; Cheng Y; Ku J; Vega Daily L; Takhar H; Song J; Chmielewski-Yee E; Spence O; Seifert H; Oraichi D; Tseng HF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327145. PubMed ID: 38488143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.